{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:59:41Z","timestamp":1790711981919,"version":"4.1.0"},"reference-count":449,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"am","delay-in-days":438,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL98416"],"award-info":[{"award-number":["R01-HL98416"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CBET-1402756"],"award-info":[{"award-number":["CBET-1402756"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS-NIH","doi-asserted-by":"publisher","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.addr.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T09:04:18Z","timestamp":1494493458000},"page":"109-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":149,"special_numbering":"C","title":["Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives"],"prefix":"10.1016","volume":"118","author":[{"given":"Melani","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2017.05.004_bb0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm2217","article-title":"Lysosomes: fusion and function","volume":"8","author":"Luzio","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.nbd.2011.01.021","article-title":"Autophagy failure in Alzheimer's disease--locating the primary defect","volume":"43","author":"Nixon","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2017.05.004_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature20414","article-title":"Defects in trafficking bridge Parkinson's disease pathology and genetics","volume":"539","author":"Abeliovich","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046834","article-title":"The role of chaperone-mediated autophagy in huntingtin degradation","volume":"7","author":"Qi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.05.004_bb0025","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0030","series-title":"Fabry Disease: Perspectives from 5Years of FOS","article-title":"Epidemiology of Lysosomal Storage Diseases: An Overview","author":"Fuller","year":"2006"},{"key":"10.1016\/j.addr.2017.05.004_bb0035","first-page":"49","article-title":"The separation and characterization of subcellular particles","volume":"59","author":"De Duve","year":"1965","journal-title":"Harvey Lect."},{"key":"10.1016\/j.addr.2017.05.004_bb0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1083\/jcb.2.4.179","article-title":"Electron microscopy of lysosome rich fractions from rat liver","volume":"2","author":"Novikoff","year":"1956","journal-title":"J. Biophys. Biochem. Cytol."},{"key":"10.1016\/j.addr.2017.05.004_bb0045","doi-asserted-by":"crossref","first-page":"14166","DOI":"10.1074\/jbc.M114.628891","article-title":"Vacuolar ATPase in phagosome-lysosome fusion","volume":"290","author":"Kissing","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0050","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev.bi.55.070186.003311","article-title":"Acidification of the endocytic and exocytic pathways","volume":"55","author":"Mellman","year":"1986","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.addr.2017.05.004_bb0055","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"433","article-title":"The Biogenesis of Membranes and Organelles","author":"Sabatini","year":"2001"},{"key":"10.1016\/j.addr.2017.05.004_bb0060","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/tra.12056","article-title":"Lysosomal membrane proteins and their central role in physiology","volume":"14","author":"Schwake","year":"2013","journal-title":"Traffic (Copenhagen, Denmark)"},{"issue":"Pt 15","key":"10.1016\/j.addr.2017.05.004_bb0065","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1242\/jcs.112.15.2473","article-title":"A human intracellular apyrase-like protein, LALP70, localizes to lysosomal\/autophagic vacuoles","volume":"112","author":"Biederbick","year":"1999","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb0070","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ceca.2011.03.010","article-title":"Lysosomal Ca2+ homeostasis: role in pathogenesis of lysosomal storage diseases","volume":"50","author":"Lloyd-Evans","year":"2011","journal-title":"Cell Calcium"},{"key":"10.1016\/j.addr.2017.05.004_bb0075","doi-asserted-by":"crossref","first-page":"12109","DOI":"10.1038\/ncomms12109","article-title":"MCOLN1 is a ROS sensor in lysosomes that regulates autophagy","volume":"7","author":"Zhang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0092-8674(84)90520-8","article-title":"Protein translocation across the endoplasmic reticulum","volume":"38","author":"Walter","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1096\/fasebj.1.6.3315809","article-title":"Trafficking of lysosomal enzymes","volume":"1","author":"Kornfeld","year":"1987","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2017.05.004_bb0090","first-page":"138","article-title":"Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes","author":"Kornfeld","year":"1982","journal-title":"CIBA Found. Symp."},{"key":"10.1016\/j.addr.2017.05.004_bb0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1083\/jcb.93.1.135","article-title":"Biosynthesis of lysosomal hydrolases: their synthesis in bound polysomes and the role of co- and post-translational processing in determining their subcellular distribution","volume":"93","author":"Rosenfeld","year":"1982","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of \u03b2-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb0105","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1600-0854.2006.00429.x","article-title":"The lysosomal trafficking of acid sphingomyelinase is mediated by sortilin and mannose 6-phosphate receptor","volume":"7","author":"Ni","year":"2006","journal-title":"Traffic (Copenhagen, Denmark)"},{"key":"10.1016\/j.addr.2017.05.004_bb0110","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2008.06.021","article-title":"Sortilin mediates the lysosomal targeting of cathepsins D and H","volume":"373","author":"Canuel","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb0115","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1093\/emboj\/cdg629","article-title":"The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin","volume":"22","author":"Lefrancois","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2017.05.004_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI112262","article-title":"Trafficking of lysosomal enzymes in normal and disease states","volume":"77","author":"Kornfeld","year":"1986","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.addr.2017.05.004_bb0125","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1016\/S0021-9258(18)43435-7","article-title":"Phosphomannosyl-enzyme receptors in rat liver. Subcellular distribution and role in intracellular transport of lysosomal enzymes","volume":"255","author":"Fischer","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/030098589703400601","article-title":"Lysosomal storage diseases of animals: an essay in comparative pathology","volume":"34","author":"Jolly","year":"1997","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.addr.2017.05.004_bb0135","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0962-8924(00)01794-3","article-title":"Regulated secretion of conventional lysosomes","volume":"10","author":"Andrews","year":"2000","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrm1665","article-title":"An emergency response team for membrane repair","volume":"6","author":"McNeil","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0145","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.bbamcr.2008.08.003","article-title":"The yeast lysosome-like vacuole: endpoint and crossroads","volume":"1793","author":"Li","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.004_bb0150","first-page":"1265","article-title":"Lysosome-related organelles","volume":"14","author":"Dell'Angelica","year":"2000","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.addr.2017.05.004_bb0155","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0160","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nrm2546","article-title":"One step at a time: endoplasmic reticulum-associated degradation","volume":"9","author":"Vembar","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0165","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/humu.20040","article-title":"Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency","volume":"23","author":"Cosma","year":"2004","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.addr.2017.05.004_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0092-8674(95)90314-3","article-title":"A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency","volume":"82","author":"Schmidt","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb0175","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1016\/j.febslet.2010.04.047","article-title":"Defective cholesterol trafficking in Niemann-pick C-deficient cells","volume":"584","author":"Peake","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2017.05.004_bb0180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1023\/A:1005640214408","article-title":"Lysosomal transport disorders","volume":"23","author":"Mancini","year":"2000","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2017.05.004_bb0185","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/hmg\/9.17.2471","article-title":"Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel","volume":"9","author":"Sun","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb0190","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/35022604","article-title":"Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease)","volume":"406","author":"Nishino","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb0195","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI0215420","article-title":"Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-pick C cells","volume":"109","author":"Choudhury","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.05.004_bb0200","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/emboj\/21.6.1289","article-title":"Late endosome motility depends on lipids via the small GTPase Rab7","volume":"21","author":"Lebrand","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2017.05.004_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-8993(76)90245-6","article-title":"Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease","volume":"116","author":"Purpura","year":"1976","journal-title":"Brain Res."},{"key":"10.1016\/j.addr.2017.05.004_bb0210","doi-asserted-by":"crossref","first-page":"21673","DOI":"10.1074\/jbc.274.31.21673","article-title":"Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons","volume":"274","author":"Korkotian","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0215","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.molcel.2004.08.029","article-title":"GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis","volume":"15","author":"Tessitore","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb0220","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrn1725","article-title":"Storage solutions: treating lysosomal disorders of the brain","volume":"6","author":"Jeyakumar","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.addr.2017.05.004_bb0225","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","article-title":"Lysosomal disorders: from storage to cellular damage","volume":"1793","author":"Ballabio","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.004_bb0230","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0962-8924(00)01847-X","article-title":"Jamming the endosomal system: lipid rafts and lysosomal storage diseases","volume":"10","author":"Simons","year":"2000","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0235","doi-asserted-by":"crossref","first-page":"a004804","DOI":"10.1101\/cshperspect.a004804","article-title":"Lysosomal lipid storage diseases","volume":"3","author":"Schulze","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0240","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature04399","article-title":"Role of cholesterol and lipid organization in disease","volume":"438","author":"Maxfield","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb0245","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.nbd.2014.02.012","article-title":"Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe's disease","volume":"66","author":"Teixeira","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.addr.2017.05.004_bb0250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/8861","article-title":"Action of BTN1, the yeast orthologue of the gene mutated in Batten disease","volume":"22","author":"Pearce","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb0255","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/hmg\/ddh067","article-title":"Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel","volume":"13","author":"Raychowdhury","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13346-012-0072-4","article-title":"Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders","volume":"2","author":"Muro","year":"2012","journal-title":"Drug Delivery and Translational Research"},{"key":"10.1016\/j.addr.2017.05.004_bb0265","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1242\/jcs.034298","article-title":"Inhibitors of the V(0) subunit of the vacuolar H(+)-ATPase prevent segregation of lysosomal- and secretory-pathway proteins","volume":"122","author":"Sobota","year":"2009","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb0270","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/cdd.2014.4","article-title":"High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann pick disease type a","volume":"21","author":"Gabande-Rodriguez","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.addr.2017.05.004_bb0275","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nm.1876","article-title":"Niemann-pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium","volume":"14","author":"Lloyd-Evans","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0280","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.beem.2014.08.005","article-title":"Non-neuronopathic lysosomal storage disorders: disease spectrum and treatments","volume":"29","author":"Pastores","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb0285","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2005-872810","article-title":"Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities","volume":"36","author":"Hoffmann","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.addr.2017.05.004_bb0290","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1038\/537S151a","article-title":"Perspective: the rare must become common","volume":"537","author":"Patterson","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb0295","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1038\/537S162a","article-title":"Screening: baby's first test","volume":"537","author":"Gupta","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb0300","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ddrr.1117","article-title":"Newborn screening for lysosomal storage disorders and other neuronopathic conditions","volume":"17","author":"Matern","year":"2013","journal-title":"Developmental Disabilities Research Reviews"},{"key":"10.1016\/j.addr.2017.05.004_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002191","article-title":"What is the purpose of the orphan drug act?","volume":"14","author":"Herder","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0310","doi-asserted-by":"crossref","DOI":"10.4161\/rdis.26690","article-title":"Clinical studies in lysosomal storage diseases: past, present, and future","volume":"1","author":"Boudes","year":"2013","journal-title":"Rare Diseases"},{"key":"10.1016\/j.addr.2017.05.004_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.3.1","article-title":"The current status of orphan drug development in Europe and the US","volume":"3","author":"Hall","year":"2014","journal-title":"Intractable & Rare Diseases Research"},{"key":"10.1016\/j.addr.2017.05.004_bb0320","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13023-015-0262-5","article-title":"Pressure for drug development in lysosomal storage disorders \u2013 a quantitative analysis thirty years beyond the US orphan drug act","volume":"10","author":"Mechler","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.addr.2017.05.004_bb0325","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.2174\/138161211797247578","article-title":"Gene therapy for lysosomal storage diseases: progress, challenges and future prospects","volume":"17","author":"Seregin","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2017.05.004_bb0330","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Molecular therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.addr.2017.05.004_bb0335","first-page":"157","article-title":"Recent advances in gene therapy for lysosomal storage disorders","volume":"8","author":"Rastall","year":"2015","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb0340","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.004_bb0345","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb0350","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/hum.1996.7.4-537","article-title":"Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild hunter syndrome (mucopolysaccharidosis type II)","volume":"7","author":"Whitley","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb0355","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/mt.2012.82","article-title":"Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice","volume":"20","author":"Langford-Smith","year":"2012","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.addr.2017.05.004_bb0360","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/360749a0","article-title":"Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer","volume":"360","author":"Wolfe","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb0365","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase a","volume":"15","author":"Ziegler","year":"2007","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.addr.2017.05.004_bb0370","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/hum.2014.115","article-title":"Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade","volume":"26","author":"Han","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb0375","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ymgme.2014.12.300","article-title":"Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features","volume":"114","author":"Rafi","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb0380","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425247.2015.966682","article-title":"Gene therapy for neurologic manifestations of mucopolysaccharidoses","volume":"12","author":"Wolf","year":"2015","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.addr.2017.05.004_bb0385","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1089\/hum.2013.213","article-title":"Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease","volume":"25","author":"Ferla","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb0390","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1517\/14712598.2011.582036","article-title":"Gene therapy for lysosomal storage disorders","volume":"11","author":"Gritti","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb0395","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb0400","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb0405","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Human Gene Therapy. Clinical Development"},{"key":"10.1016\/j.addr.2017.05.004_bb0410","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2015.189","article-title":"Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII","volume":"24","author":"Gurda","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb0415","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/mt.2015.106","article-title":"Arylsulfatase a overexpressing human iPSC-derived neural cells reduce CNS sulfatide storage in a mouse model of metachromatic leukodystrophy","volume":"23","author":"Doerr","year":"2015","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.addr.2017.05.004_bb0420","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.stemcr.2015.02.022","article-title":"Ex vivo gene therapy using patient iPSC-derived NSCs reverses pathology in the brain of a homologous mouse model","volume":"4","author":"Griffin","year":"2015","journal-title":"Stem cell reports"},{"key":"10.1016\/j.addr.2017.05.004_bb0425","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3171\/2013.3.PEDS12397","article-title":"Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis","volume":"11","author":"Selden","year":"2013","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.addr.2017.05.004_bb0430","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40778-014-0007-8","article-title":"Genome editing: potential treatment for lysosomal storage diseases","volume":"1","author":"de Carvalho","year":"2015","journal-title":"Current Stem Cell Reports"},{"key":"10.1016\/j.addr.2017.05.004_bb0435","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2014-12-615492","article-title":"In vivo genome editing of the albumin locus as a platform for protein replacement therapy","volume":"126","author":"Sharma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb0440","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nbt0714-599","article-title":"First CRISPR-Cas patent opens race to stake out intellectual property","volume":"32","author":"Sheridan","year":"2014","journal-title":"Nat Biotech"},{"key":"10.1016\/j.addr.2017.05.004_bb0445","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pediatrneurol.2003.09.003","article-title":"The status of hematopoietic stem cell transplantation in lysosomal storage disease","volume":"29","author":"Malatack","year":"2003","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.addr.2017.05.004_bb0450","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb0455","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/j.addr.2017.05.004_bb0460","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0465","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/mt.2012.214","article-title":"Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis","volume":"21","author":"Harrison","year":"2013","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.addr.2017.05.004_bb0470","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.addr.2017.05.004_bb0475","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/ijms17071065","article-title":"Less is more: substrate reduction therapy for lysosomal storage disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb0480","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/ki.2011.301","article-title":"Cysteamine therapy: a treatment for cystinosis, not a cure","volume":"81","author":"Cherqui","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.addr.2017.05.004_bb0485","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1194\/jlr.R047837","article-title":"Niemann-pick C disease and mobilization of lysosomal cholesterol by cyclodextrin","volume":"55","author":"Vance","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2017.05.004_bb0490","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymgmr.2014.08.004","article-title":"Effects of intracerebroventricular administration of 2-hydroxypropyl-\u03b2-cyclodextrin in a patient with Niemann\u2013pick type C disease","volume":"1","author":"Matsuo","year":"2014","journal-title":"Molecular Genetics and Metabolism Reports"},{"key":"10.1016\/j.addr.2017.05.004_bb0495","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1248\/bpb.b14-00726","article-title":"Efficacy of 2-hydroxypropyl-beta-cyclodextrin in Niemann-pick disease type C model mice and its pharmacokinetic analysis in a patient with the disease","volume":"38","author":"Tanaka","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2017.05.004_bb0500","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/acn3.306","article-title":"Efficacy and ototoxicity of different cyclodextrins in Niemann\u2013pick C disease","volume":"3","author":"Davidson","year":"2016","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/j.addr.2017.05.004_bb0505","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/B:BOLI.0000031101.12838.c6","article-title":"Enzyme replacement and enhancement therapies for lysosomal diseases","volume":"27","author":"Desnick","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2017.05.004_bb0510","first-page":"145","article-title":"Emerging novel concept of chaperone therapies for protein misfolding diseases, proceedings of the Japan academy","volume":"90","author":"Suzuki","year":"2014","journal-title":"Series B, Physical and Biological Sciences"},{"key":"10.1016\/j.addr.2017.05.004_bb0515","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0520","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00018-008-7470-2","article-title":"Chemical chaperone therapy for GM1-gangliosidosis","volume":"65","author":"Suzuki","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb0525","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2017.05.004_bb0530","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature08710","article-title":"Hsp70 stabilizes lysosomes and reverts Niemann-pick disease-associated lysosomal pathology","volume":"463","author":"Kirkegaard","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb0535","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9823","article-title":"Heat shock protein\u2013based therapy as a potential candidate for treating the sphingolipidoses","volume":"8","author":"Kirkegaard","year":"2016","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.addr.2017.05.004_bb0540","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1096\/fj.04-2714fje","article-title":"Protein transduction of Rab9 in Niemann-pick C cells reduces cholesterol storage","volume":"19","author":"Narita","year":"2005","journal-title":"FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.addr.2017.05.004_bb0545","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1194\/jlr.R046896","article-title":"Lysosomal exocytosis and lipid storage disorders","volume":"55","author":"Samie","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2017.05.004_bb0550","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.devcel.2011.07.016","article-title":"Transcriptional activation of lysosomal exocytosis promotes cellular clearance","volume":"21","author":"Medina","year":"2011","journal-title":"Dev. Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb0555","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.addr.2017.05.004_bb0560","doi-asserted-by":"crossref","first-page":"39349","DOI":"10.1074\/jbc.M112.357707","article-title":"Delta-tocopherol reduces lipid accumulation in Niemann-pick type C1 and Wolman cholesterol storage disorders","volume":"287","author":"Xu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015054","article-title":"Cyclodextrin induces calcium-dependent lysosomal exocytosis","volume":"5","author":"Chen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.05.004_bb0570","doi-asserted-by":"crossref","first-page":"26279","DOI":"10.1074\/jbc.M110.134775","article-title":"Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-pick type C disease","volume":"285","author":"Strauss","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0575","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/ncomms1735","article-title":"Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release","volume":"3","author":"Shen","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002583","article-title":"Lysosomal re-acidification prevents lysosphingolipid-induced lysosomal impairment and cellular toxicity","volume":"14","author":"Folts","year":"2016","journal-title":"PLoS Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049635","article-title":"Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells","volume":"7","author":"Baltazar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.05.004_bb0590","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJM196608112750606","article-title":"The Sphingolipidoses","volume":"275","author":"Brady","year":"1966","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addr.2017.05.004_bb0595","first-page":"1045","article-title":"From cytases to lysosomes","volume":"23","author":"Deduve","year":"1964","journal-title":"Fed. Proc."},{"key":"10.1016\/j.addr.2017.05.004_bb0600","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.004_bb0605","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1073\/pnas.64.1.360","article-title":"The defect in hurler and hunter S","volume":"64","author":"Fratantoni","year":"1969","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.addr.2017.05.004_bb0610","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1016\/S0021-9258(20)81127-2","article-title":"The hunter corrective factor. Purification and preliminary characterization","volume":"247","author":"Cantz","year":"1972","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0615","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1073\/pnas.69.8.2048","article-title":"The defect in the hurler and Scheie syndromes: deficiency of \u03b1-l-iduronidase","volume":"69","author":"Bach","year":"1972","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0620","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(71)92435-4","article-title":"I-cell disease: multiple lysosomal-enzyme defect","volume":"1","author":"Lightbody","year":"1971","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.addr.2017.05.004_bb0625","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/0006-291X(72)90310-5","article-title":"A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes","volume":"49","author":"Hickman","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb0630","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-9861(76)90061-8","article-title":"The relationship of \u03b1-l-iduronidase and hurler corrective factor","volume":"172","author":"Shapiro","year":"1976","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.addr.2017.05.004_bb0635","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0006-291X(74)80356-6","article-title":"A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts","volume":"57","author":"Hickman","year":"1974","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb0640","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/9780470122860.ch3","article-title":"The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins","volume":"41","author":"Ashwell","year":"1974","journal-title":"Adv. Enzymol. Relat. Areas Mol. Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0645","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1073\/pnas.74.5.2026","article-title":"Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts","volume":"74","author":"Kaplan","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0650","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1073\/pnas.76.5.2331","article-title":"Direct demonstration of binding of a lysosomal enzyme, alpha-l-iduronidase, to receptors on cultured fibroblasts","volume":"76","author":"Rome","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0655","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1016\/S0021-9258(19)70385-8","article-title":"Structural studies of phosphorylated high mannose-type oligosaccharides","volume":"255","author":"Varki","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0660","series-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Scriver","year":"2000"},{"key":"10.1016\/j.addr.2017.05.004_bb0665","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0021-9258(18)96226-5","article-title":"The metabolism of ceramide trihexosides. I. Purification and properties of an enzyme that cleaves the terminal galactose molecule of galactosylgalactosylglucosylceramide","volume":"242","author":"Brady","year":"1967","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0670","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM197411072911901","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease","volume":"291","author":"Brady","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0675","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM197307052890103","article-title":"Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease","volume":"289","author":"Brady","year":"1973","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0680","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/S0021-9258(19)43595-3","article-title":"Isolation and characterization of glucocerebrosidase from human placental tissue","volume":"248","author":"Pentchev","year":"1973","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0685","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1073\/pnas.74.8.3560","article-title":"Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration","volume":"74","author":"Furbish","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0690","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0003-9861(76)90471-9","article-title":"Clearance of lysosomal hydrolases following intravenous infusion. Kinetic and competition experiments with beta-glucuronidase and N-acetyl-beta-d-glucosaminidase","volume":"177","author":"Stahl","year":"1976","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.addr.2017.05.004_bb0695","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0304-4165(81)90474-8","article-title":"Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation","volume":"673","author":"Furbish","year":"1981","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.004_bb0700","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1042\/bj1760103","article-title":"Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver non-parenchymal cells. Studies with beta-glucuronidase, N-acetyl-beta-D-glucosaminidase, ribonuclease B and agalacto-orosomucoid","volume":"176","author":"Schlesinger","year":"1978","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.addr.2017.05.004_bb0705","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0092-8674(78)90102-2","article-title":"Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells","volume":"15","author":"Achord","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb0710","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1016\/S0021-9258(18)90936-1","article-title":"Structure of the N-asparagine-linked oligosaccharide units of human placental beta-glucocerebrosidase","volume":"259","author":"Takasaki","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0715","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","article-title":"Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease","volume":"87","author":"Barton","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0720","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency \u2014 macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0725","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0014-5793(96)01331-2","article-title":"Purification of acid sphingomyelinase from human placenta: characterization and N-terminal sequence","volume":"399","author":"Lansmann","year":"1996","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2017.05.004_bb0730","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1073\/pnas.76.10.5326","article-title":"Enzyme therapy in Fabry disease: differential in vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase a isozymes","volume":"76","author":"Desnick","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0735","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bj1450113","article-title":"Purification of normal human urinary N-acetyl-beta-hexosaminidase a by affinity chromatography","volume":"145","author":"Banerjee","year":"1975","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.addr.2017.05.004_bb0740","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0076-6879(91)97180-7","article-title":"Human acid sphingomyelinase from human urine","volume":"197","author":"Quintern","year":"1991","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2017.05.004_bb0745","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/0003-9861(78)90221-7","article-title":"Human kidney alpha-l-iduronidase: purification and characterization","volume":"189","author":"Rome","year":"1978","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.addr.2017.05.004_bb0750","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/S0021-9258(17)43271-6","article-title":"Human alpha-l-iduronidase. I. Purification and properties of the high uptake (higher molecular weight) and the low uptake (processed) forms","volume":"259","author":"Schuchman","year":"1984","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0755","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1042\/bj2480755","article-title":"Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values","volume":"248","author":"Gibson","year":"1987","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.addr.2017.05.004_bb0760","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1016\/S0021-9258(18)33554-3","article-title":"Purification and properties of feline and human arylsulfatase B isozymes. Evidence for feline homodimeric and human monomeric structures","volume":"257","author":"McGovern","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0765","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj2590199","article-title":"Immunopurification and characterization of human alpha-l-iduronidase with the use of monoclonal antibodies","volume":"259","author":"Clements","year":"1989","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.addr.2017.05.004_bb0770","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/bj2710075","article-title":"Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties","volume":"271","author":"Bielicki","year":"1990","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.addr.2017.05.004_bb0775","doi-asserted-by":"crossref","first-page":"28348","DOI":"10.1074\/jbc.271.45.28348","article-title":"Cloning, expression, purification, and characterization of the human broad specificity lysosomal acid \u03b1-mannosidase","volume":"271","author":"Liao","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0780","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1432-1033.1994.tb18572.x","article-title":"Purification, characterization and molecular cloning of human hepatic lysosomal acid lipase","volume":"219","author":"Ameis","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.addr.2017.05.004_bb0785","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0790","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood.V93.9.2807.409k08_2807_2816","article-title":"A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease","volume":"93","author":"Friedman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb0795","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1083\/jcb.119.5.1137","article-title":"Overexpression of human alpha-galactosidase a results in its intracellular aggregation, crystallization in lysosomes, and selective secretion","volume":"119","author":"Ioannou","year":"1992","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0800","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1042\/bj2840789","article-title":"Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase","volume":"284","author":"Anson","year":"1992","journal-title":"The Biochemical journal"},{"issue":"Pt 1","key":"10.1016\/j.addr.2017.05.004_bb0805","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/bj2890241","article-title":"Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme","volume":"289","author":"Bielicki","year":"1993","journal-title":"The Biochemical journal"},{"issue":"Pt 1","key":"10.1016\/j.addr.2017.05.004_bb0810","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1042\/bj3040043","article-title":"Recombinant alpha-l-iduronidase: characterization of the purified enzyme and correction of mucopolysaccharidosis type I fibroblasts","volume":"304","author":"Unger","year":"1994","journal-title":"The Biochemical journal"},{"key":"10.1016\/j.addr.2017.05.004_bb0815","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1006\/prep.1994.1035","article-title":"Overexpression of the human lysosomal enzyme alpha-l-iduronidase in Chinese hamster ovary cells","volume":"5","author":"Kakkis","year":"1994","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.addr.2017.05.004_bb0820","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.addr.2017.05.004_bb0825","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1096\/fj.00-0014com","article-title":"Infusion of recombinant human acid sphingomyelinase into niemann-pick disease mice leads to visceral, but not neurological, correction of the pathophysiology","volume":"14","author":"Miranda","year":"2000","journal-title":"FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.addr.2017.05.004_bb0830","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ymgme.2014.07.005","article-title":"Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency:the utility of animal models of disease in the toxicological evaluation of potential therapeutics","volume":"114","author":"Murray","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb0835","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/mgme.2001.3173","article-title":"Purification and characterization of recombinant human lysosomal \u03b1-mannosidase","volume":"73","author":"Berg","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb0840","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s10038-005-0278-0","article-title":"Establishment of immortalized Schwann cells from Sandhoff mice and corrective effect of recombinant human beta-hexosaminidase a on the accumulated GM2 ganglioside","volume":"50","author":"Ohsawa","year":"2005","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb0845","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/hmg\/ddi126","article-title":"Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy","volume":"14","author":"Matzner","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb0850","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0855","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","article-title":"Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease","volume":"94","author":"McVie-Wylie","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb0860","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1073\/pnas.0712147105","article-title":"Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII","volume":"105","author":"Grubb","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb0865","doi-asserted-by":"crossref","first-page":"10551","DOI":"10.1016\/S0021-9258(18)67420-4","article-title":"Lec1A Chinese hamster ovary cell mutants appear to arise from a structural alteration in N-acetylglucosaminyltransferase I","volume":"261","author":"Chaney","year":"1986","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0870","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(75)90002-1","article-title":"Selection and characterization of eight phenotypically distinct lines of lectin-resistant Chinese hamster ovary cells","volume":"6","author":"Stanley","year":"1975","journal-title":"Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb0875","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1172\/JCI118617","article-title":"Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome","volume":"97","author":"Crawley","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.05.004_bb0880","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/prep.2000.1230","article-title":"Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells","volume":"19","author":"Zhao","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.addr.2017.05.004_bb0885","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4161\/bioe.29490","article-title":"Producing recombinant therapeutic glycoproteins with enhanced sialylation using CHO-gmt4 glycosylation mutant cells","volume":"5","author":"Goh","year":"2014","journal-title":"Bioengineered"},{"issue":"2011","key":"10.1016\/j.addr.2017.05.004_bb0890","first-page":"515","article-title":"Velaglucerase alfa: a new option for Gaucher disease treatment","volume":"47","author":"Zimran","year":"1998","journal-title":"Drugs of Today (Barcelona, Spain)"},{"key":"10.1016\/j.addr.2017.05.004_bb0895","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/glycob\/cwm008","article-title":"Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease","volume":"17","author":"Van Patten","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.004_bb0900","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-\u03b2-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.004_bb0905","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1096\/fasebj.14.2.361","article-title":"Enzyme replacement therapy in a mouse model of aspartylglycosaminuria","volume":"14","author":"Dunder","year":"2000","journal-title":"FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.addr.2017.05.004_bb0910","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/BA20030184","article-title":"A simple method for the production of recombinant proteins from mammalian cells","volume":"40","author":"Wu","year":"2004","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.addr.2017.05.004_bb0915","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s001090050279","article-title":"Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes","volume":"76","author":"Liu","year":"1998","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb0920","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","article-title":"Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II","volume":"8","author":"Bijvoet","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb0925","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human \u03b1-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.addr.2017.05.004_bb0930","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.26289","article-title":"Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease","volume":"58","author":"Balwani","year":"2013","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.addr.2017.05.004_bb0935","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/0076-6879(72)28105-8","article-title":"[99] \u03b1-N-acetylglucosaminidase from hen oviduct","volume":"28","author":"Tabentino","year":"1972","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2017.05.004_bb0940","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5582\/ddt.2016.01024","article-title":"Recent progress in development of transgenic silkworms overexpressing recombinant human proteins with therapeutic potential in silk glands","volume":"10","author":"Itoh","year":"2016","journal-title":"Drug Discoveries & Therapeutics"},{"key":"10.1016\/j.addr.2017.05.004_bb0945","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/dna.1988.7.99","article-title":"Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector","volume":"7","author":"Martin","year":"1988","journal-title":"DNA (Mary Ann Liebert, Inc.)"},{"key":"10.1016\/j.addr.2017.05.004_bb0950","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1139\/o05-165","article-title":"Secretion of human glucocerebrosidase from stable transformed insect cells using native signal sequences","volume":"84","author":"Sinclair","year":"2006","journal-title":"Biochemistry and Cell Biology"},{"key":"10.1016\/j.addr.2017.05.004_bb0955","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1074\/jbc.M110.150433","article-title":"X-ray and biochemical analysis of N370S mutant human acid beta-glucosidase","volume":"286","author":"Wei","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb0960","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1096\/fj.03-0941fje","article-title":"Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis","volume":"18","author":"Bonten","year":"2004","journal-title":"FASEB Journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.addr.2017.05.004_bb0965","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0378-1119(94)90378-6","article-title":"Characterization of glycosylated and catalytically active recombinant human alpha-galactosidase a using a baculovirus vector","volume":"144","author":"Coppola","year":"1994","journal-title":"Gene"},{"key":"10.1016\/j.addr.2017.05.004_bb0970","first-page":"755","article-title":"Expression of catalytically active human multifunctional glycogen-debranching enzyme and lysosomal acid alpha-glucosidase in insect cells","volume":"39","author":"Wu","year":"1996","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.addr.2017.05.004_bb0975","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/1046-5928(90)90003-H","article-title":"Synthesis of a human lysosomal enzyme, beta-hexosaminidase B, using the baculovirus expression system","volume":"1","author":"Boose","year":"1990","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.addr.2017.05.004_bb0980","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0076-6879(00)11075-4","article-title":"Purification and characterization of recombinant human acid sphingomyelinase expressed in insect Sf21 cells","volume":"311","author":"Lansmann","year":"2000","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2017.05.004_bb0985","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jmb.2012.08.020","article-title":"The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV a","volume":"423","author":"Rivera-Colon","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb0990","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0024-3205(02)01917-3","article-title":"Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus","volume":"71","author":"Sperker","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb0995","first-page":"679","article-title":"Plants as factories for production of biopharmaceutical and bioindustrial proteins: lessons from cell biology this review is one of a selection of papers published in the special issue on plant cell biology","volume":"84","author":"Kermode","year":"2006","journal-title":"Botany"},{"key":"10.1016\/j.addr.2017.05.004_bb1000","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/glycob\/6.4.471","article-title":"Role of complex asparagine-linked glycans in the allergenicity of plant glycoproteins","volume":"6","author":"Garcia-Casado","year":"1996","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.004_bb1005","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/ncomms2070","article-title":"Production of \u03b1-l-iduronidase in maize for the potential treatment of a human lysosomal storage disease","volume":"3","author":"He","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb1010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.addr.2017.05.004_bb1015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004792","article-title":"A plant-derived recombinant human glucocerebrosidase enzyme\u2014a preclinical and phase I investigation","volume":"4","author":"Aviezer","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.05.004_bb1020","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/glycob\/cwr157","article-title":"Production of active human glucocerebrosidase in seeds of Arabidopsis thaliana Complex-glycan-deficient (cgl) plants","volume":"22","author":"He","year":"2011","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.004_bb1025","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/pbi.12096","article-title":"Characterization and downstream mannose phosphorylation of human recombinant \u03b1-l-iduronidase produced in Arabidopsis Complex glycan-deficient (cgl) seeds","volume":"11","author":"He","year":"2013","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.addr.2017.05.004_bb1030","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/pcp\/pcn108","article-title":"Purification, cloning and functional characterization of an endogenous beta-glucuronidase in Arabidopsis thaliana","volume":"49","author":"Eudes","year":"2008","journal-title":"Plant & cell physiology"},{"key":"10.1016\/j.addr.2017.05.004_bb1035","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1194\/jlr.M700482-JLR200","article-title":"Wolman disease\/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice","volume":"49","author":"Du","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.addr.2017.05.004_bb1040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","article-title":"Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase a efficiently corrects enzyme deficiency in Fabry mice","volume":"39","author":"Shen","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.addr.2017.05.004_bb1045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11103-004-6832-x","article-title":"Recombinant human acid beta-glucosidase stored in tobacco seed is stable, active and taken up by human fibroblasts","volume":"57","author":"Reggi","year":"2005","journal-title":"Plant Mol. Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb1050","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human alpha-galactosidase-a enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1055","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.plantsci.2015.08.018","article-title":"The combination of plant translational enhancers and terminator increase the expression of human glucocerebrosidase in Nicotiana benthamiana plants","volume":"240","author":"Limkul","year":"2015","journal-title":"Plant Science: An International Journal of experimental plant biology"},{"key":"10.1016\/j.addr.2017.05.004_bb1060","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1248\/bpb.32.786","article-title":"Glycan engineering and production of 'humanized' glycoprotein in yeast cells","volume":"32","author":"Chiba","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.addr.2017.05.004_bb1065","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1086\/498652","article-title":"The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy","volume":"77","author":"Du","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1006\/prep.2000.1325","article-title":"Expression and characterization of glycosylated and catalytically active recombinant human \u03b1-galactosidase a produced in Pichia Pastoris","volume":"20","author":"Chen","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.addr.2017.05.004_bb1075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1046-5928(02)00526-0","article-title":"Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast, Pichia pastoris","volume":"26","author":"Sinclair","year":"2002","journal-title":"Protein Expression and Purification"},{"key":"10.1016\/j.addr.2017.05.004_bb1080","doi-asserted-by":"crossref","first-page":"29329","DOI":"10.1038\/srep29329","article-title":"Recombinant human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) produced in the methylotrophic yeast Pichia pastoris","volume":"6","author":"Rodr\u00edguez-L\u00f3pez","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.addr.2017.05.004_bb1085","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.ymgme.2012.11.082","article-title":"Production of human recombinant alpha-N-acetylglucosaminidase enzymes in two Pichia pastoris strains","volume":"108","author":"Espejo-Mojica","year":"2013","journal-title":"Molecular Genetics and Metabolism"},{"key":"10.1016\/j.addr.2017.05.004_bb1090","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/AEM.00463-07","article-title":"Production of recombinant \u03b2-hexosaminidase a, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta","volume":"73","author":"Akeboshi","year":"2007","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.addr.2017.05.004_bb1095","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/glycob\/cwp080","article-title":"Production of human \u03b2-hexosaminidase a with highly phosphorylated N-glycans by the overexpression of the Ogataea minuta MNN4 gene","volume":"19","author":"Akeboshi","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.004_bb1100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2119\/molmed.2011.00248","article-title":"Efficient uptake of recombinant \u03b1-galactosidase a produced with a gene-manipulated yeast by fabry mice kidneys","volume":"18","author":"Tsukimura","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb1105","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/nbt.2427","article-title":"A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes","volume":"30","author":"Tiels","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb1110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039976","article-title":"Engineering Yarrowia lipolytica to produce glycoproteins homogeneously modified with the universal Man3GlcNAc2 N-glycan core","volume":"7","author":"De Pourcq","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.05.004_bb1115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0006-291X(90)91285-Z","article-title":"Expression of human lysosomal \u03b2-hexosaminidase in yeast vacuoles","volume":"170","author":"Prezant","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb1120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jbiotec.2015.04.007","article-title":"Increased mannosylphosphorylation of N-glycans by heterologous expression of YlMPO1 in glyco-engineered Saccharomyces cerevisiae for mannose-6-phosphate modification","volume":"206","author":"Gil","year":"2015","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb1125","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/glycob\/cwf096","article-title":"Production in yeast of \u03b1-galactosidase a, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease","volume":"12","author":"Chiba","year":"2002","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.004_bb1130","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1389-1723(04)00297-X","article-title":"Production of recombinant human lysosomal acid lipase in Schizosaccharomyces pombe: development of a fed-batch fermentation and purification process","volume":"98","author":"Ikeda","year":"2004","journal-title":"J. Biosci. Bioeng."},{"key":"10.1016\/j.addr.2017.05.004_bb1135","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2015.06.001","article-title":"Human recombinant lysosomal enzymes produced in microorganisms","volume":"116","author":"Espejo-Mojica","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0168-1656(98)00070-4","article-title":"Expression of recombinant human acid sphingomyelinase in insect Sf21 cells: purification, processing and enzymatic characterization","volume":"63","author":"Bartelsen","year":"1998","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb1145","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.procbio.2012.07.028","article-title":"Characterization of a recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in E. coli for enzyme replacement therapy of Morquio a disease","volume":"47","author":"Mosquera","year":"2012","journal-title":"Process Biochem."},{"key":"10.1016\/j.addr.2017.05.004_bb1150","first-page":"213","article-title":"Low-scale expression and purification of an active putative iduronate 2-sulfate sulfatase-like enzyme from Escherichia coli K12","volume":"51","author":"Morales-Alvarez","year":"2013","journal-title":"Journal of Microbiology (Seoul, Korea)"},{"key":"10.1016\/j.addr.2017.05.004_bb1155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1874285801610010124","article-title":"Bioinformatic analysis of the human recombinant iduronate 2-sulfate sulfatase","volume":"10","author":"Morales-Alvarez","year":"2016","journal-title":"The Open Microbiology Journal"},{"key":"10.1016\/j.addr.2017.05.004_bb1160","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1007\/s00253-014-6328-9","article-title":"Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase a","volume":"99","author":"Unzueta","year":"2015","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb1165","first-page":"229","article-title":"Animal model of human disease: Niemann-pick disease type C","volume":"85","author":"Adachi","year":"1976","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2017.05.004_bb1170","first-page":"394","article-title":"The twitcher mouse. A model of human globoid cell leukodystrophy (Krabbe's disease)","volume":"111","author":"Suzuki","year":"1983","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2017.05.004_bb1175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02834075","article-title":"Genetic galactosylceramidase deficiency (globoid cell leukodystrophy, Krabbe disease) in different mammalian species","volume":"3","author":"Suzuki","year":"1983","journal-title":"Neurochem. Pathol."},{"key":"10.1016\/j.addr.2017.05.004_bb1180","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/glycob\/9.12.1389","article-title":"A mouse model for mucopolysaccharidosis type III a (Sanfilippo syndrome)","volume":"9","author":"Bhaumik","year":"1999","journal-title":"Glycobiology"},{"key":"10.1016\/j.addr.2017.05.004_bb1185","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.174.4011.838","article-title":"Neuronal GM1 gangliosidosis in a Siamese cat with beta-galactosidase deficiency","volume":"174","author":"Baker","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.004_bb1190","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1203\/01.PDR.0000156510.96253.5A","article-title":"Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models","volume":"57","author":"Simonaro","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2017.05.004_bb1195","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.144321","article-title":"Mucopolysaccharidosis in a cat with arylsulfatase B deficiency: a model of Maroteaux-Lamy syndrome","volume":"198","author":"Jezyk","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.004_bb1200","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00334507","article-title":"Feline sphingolipidosis resembling Niemann-pick disease type C","volume":"81","author":"Lowenthal","year":"1990","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.addr.2017.05.004_bb1205","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1172\/JCI111997","article-title":"Characterization of a new model of GM2-gangliosidosis (Sandhoff's disease) in Korat cats","volume":"76","author":"Neuwelt","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.05.004_bb1210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2009.01.003","article-title":"Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency","volume":"97","author":"Bradbury","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1215","first-page":"980","article-title":"Beta-glucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII","volume":"18","author":"Haskins","year":"1984","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.addr.2017.05.004_bb1220","doi-asserted-by":"crossref","first-page":"12937","DOI":"10.1073\/pnas.91.26.12937","article-title":"Enzyme replacement in a canine model of hurler syndrome","volume":"91","author":"Shull","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1225","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1172\/JCI116268","article-title":"Arylsulfatase B-deficient mucopolysaccharidosis in rats","volume":"91","author":"Yoshida","year":"1993","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.addr.2017.05.004_bb1230","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI1722","article-title":"Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail","volume":"101","author":"Kikuchi","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.05.004_bb1235","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/6.4.503","article-title":"Murine mucopolysaccharidosis type I: targeted disruption of the murine \u03b1-l-iduronidase gene","volume":"6","author":"Clarke","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1240","doi-asserted-by":"crossref","first-page":"14505","DOI":"10.1073\/pnas.96.25.14505","article-title":"Mouse model of Sanfilippo syndrome type B produced by targeted disruption of the gene encoding \u03b1-N-acetylglucosaminidase","volume":"96","author":"Li","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb1245","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1093\/hmg\/ddi364","article-title":"Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase","volume":"14","author":"Tomatsu","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1250","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2017.05.004_bb1255","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"Alpha-galactosidase a deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1260","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1128\/MCB.22.21.7622-7632.2002","article-title":"Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis","volume":"22","author":"Cherqui","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb1265","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/ng0795-288","article-title":"Acid sphingomyelinase deficient mice: a model of types a and B Niemann-pick disease","volume":"10","author":"Horinouchi","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1270","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.1073\/pnas.93.25.14821","article-title":"Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy","volume":"93","author":"Hess","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1275","first-page":"207","article-title":"A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice","volume":"136","author":"Vogler","year":"1990","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2017.05.004_bb1280","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/nm1296-1375","article-title":"A mouse model for the human lysosomal disease aspartylglycosaminuria","volume":"2","author":"Kaartinen","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb1285","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/hmg\/10.16.1639","article-title":"Enzyme therapy for lysosomal acid lipase deficiency in the mouse","volume":"10","author":"Du","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1290","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1073\/pnas.91.21.9975","article-title":"Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease","volume":"91","author":"Yamanaka","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hmg\/5.1.1","article-title":"Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases","volume":"5","author":"Phaneuf","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1305","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.95.5.2503","article-title":"Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure","volume":"95","author":"Liu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1310","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood-2006-03-010801","article-title":"Low-dose therapy trumps high-dose therapy again in the treatment of Gaucher disease","volume":"108","author":"Zimran","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb1315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ajh.21384","article-title":"Gaucher disease: resetting the clinical and scientific agenda","volume":"84","author":"Mistry","year":"2009","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.addr.2017.05.004_bb1320","series-title":"Enzyme-Replacement Therapies for Lysosomal Storage Diseases","author":"Ratko","year":"2013"},{"key":"10.1016\/j.addr.2017.05.004_bb1325","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"The Journal of Pediatrics"},{"key":"10.1016\/j.addr.2017.05.004_bb1330","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-014-0108-z","article-title":"Elosulfase alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio a syndrome)","volume":"28","author":"Lyseng-Williamson","year":"2014","journal-title":"BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy"},{"key":"10.1016\/j.addr.2017.05.004_bb1335","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1501365","article-title":"A phase 3 trial of Sebelipase alfa in lysosomal acid lipase deficiency","volume":"373","author":"Burton","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addr.2017.05.004_bb1340","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/gim.2015.24","article-title":"Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-pick disease type B (acid sphingomyelinase deficiency)","volume":"18","author":"McGovern","year":"2016","journal-title":"Genetics in Medicine: Official Journal of the American College of Medical Genetics"},{"key":"10.1016\/j.addr.2017.05.004_bb1345","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb1350","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1355","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb1360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2008.10.013","article-title":"Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?","volume":"96","author":"Hollak","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1365","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","article-title":"Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the hunter outcome survey (HOS)","volume":"103","author":"Burton","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1370","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0925-4439(97)00036-7","article-title":"Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models","volume":"1361","author":"Brooks","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.004_bb1375","doi-asserted-by":"crossref","DOI":"10.1542\/peds.100.6.e11","article-title":"Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease","volume":"100","author":"Brady","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.addr.2017.05.004_bb1380","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb1385","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1390","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00109-008-0309-3","article-title":"Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease","volume":"86","author":"Matzner","year":"2008","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb1395","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/mgme.2000.2979","article-title":"Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats","volume":"69","author":"Turner","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1400","unstructured":"Cerezyme\u00ae product sheet 4668."},{"key":"10.1016\/j.addr.2017.05.004_bb1405","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/all.12155","article-title":"IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with hunter syndrome","volume":"68","author":"Kim","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.addr.2017.05.004_bb1410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1415","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-gal a enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2017.05.004_bb1420","first-page":"S100","article-title":"Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders","volume":"47","author":"Miebach","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1425","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genetics in Medicine: Official Journal of the American College of Medical Genetics"},{"key":"10.1016\/j.addr.2017.05.004_bb1430","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2017.05.004_bb1435","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","article-title":"Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.addr.2017.05.004_bb1440","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ymgme.2015.05.013","article-title":"Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency","volume":"116","author":"Wasserstein","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1445","first-page":"915","article-title":"Enzyme replacement therapy: conception, chaos and culmination","volume":"358","author":"Brady","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb1450","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/nrg963","article-title":"Enzyme replacement and enhancement therapies: lessons from lysosomal disorders","volume":"3","author":"Desnick","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2017.05.004_bb1455","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.addr.2017.05.004_bb1460","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/10611860903548354","article-title":"Biopharmaceutical drug targeting to the brain","volume":"18","author":"Pardridge","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2017.05.004_bb1465","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000264398","article-title":"Blood-brain barrier as a regulatory interface","volume":"63","author":"Banks","year":"2009","journal-title":"Forum Nutr."},{"key":"10.1016\/j.addr.2017.05.004_bb1470","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrm1357","article-title":"Endothelial cell-cell junctions: happy together","volume":"5","author":"Dejana","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.addr.2017.05.004_bb1475","doi-asserted-by":"crossref","unstructured":"I.E. Blasig, R.F. Haseloff, Tight junctions and tissue barriers, Antioxid. Redox Signal., 15 1163\u20131166.","DOI":"10.1089\/ars.2011.4003"},{"key":"10.1016\/j.addr.2017.05.004_bb1480","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10571-004-1375-x","article-title":"In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro","volume":"25","author":"Haseloff","year":"2005","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.addr.2017.05.004_bb1485","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1474-4422(07)70326-5","article-title":"Strategies to advance translational research into brain barriers","volume":"7","author":"Neuwelt","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.addr.2017.05.004_bb1490","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/1570161043385736","article-title":"Endothelial endocytic pathways: gates for vascular drug delivery","volume":"2","author":"Muro","year":"2004","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.addr.2017.05.004_bb1495","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood-brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2017.05.004_bb1500","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/mt.2008.84","article-title":"Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse","volume":"16","author":"Urayama","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1505","unstructured":"Shire HGT. Open-label extension study of recombinant human arylsulfatase A (HGT-1111) in late infantile metachromatic leukodystrophy. ClinicalTrialsgov.NCT00681811. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00681811?term=NCT00681811&rank=1."},{"key":"10.1016\/j.addr.2017.05.004_bb1510","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb1515","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Gaucher Disease","author":"Grabowski","year":"2014"},{"key":"10.1016\/j.addr.2017.05.004_bb1520","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2014"},{"key":"10.1016\/j.addr.2017.05.004_bb1525","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Niemann-Pick Disease Types a and B: Acid Sphingomyelinase Deficiencies","author":"Schuchman","year":"2014"},{"key":"10.1016\/j.addr.2017.05.004_bb1530","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jconrel.2012.05.052","article-title":"Challenges in design and characterization of ligand-targeted drug delivery systems","volume":"164","author":"Muro","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.004_bb1535","doi-asserted-by":"crossref","first-page":"L419","DOI":"10.1152\/ajplung.2000.279.3.L419","article-title":"Mechanisms regulating endothelial cell barrier function","volume":"279","author":"Stevens","year":"2000","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.addr.2017.05.004_bb1540","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425247.2.5.909","article-title":"Biomedical aspects of targeted delivery of drugs to pulmonary endothelium","volume":"2","author":"Muzykantov","year":"2005","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.addr.2017.05.004_bb1545","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1074\/jbc.M108531200","article-title":"Multiple signals regulate trafficking of the mannose 6-phosphate-uncovering enzyme","volume":"277","author":"Lee","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb1550","first-page":"77","article-title":"The uptake of enzymes into lysosomes: an overview","volume":"16","author":"Neufeld","year":"1980","journal-title":"Birth defects original article series"},{"key":"10.1016\/j.addr.2017.05.004_bb1555","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0076-6879(87)49041-1","article-title":"Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells","volume":"149","author":"Murray","year":"1987","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.addr.2017.05.004_bb1560","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1124\/jpet.103.060236","article-title":"Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages","volume":"308","author":"Zhu","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1565","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"PathoGenetics"},{"key":"10.1016\/j.addr.2017.05.004_bb1570","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1074\/jbc.M309465200","article-title":"Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: implications for Niemann-pick disease enzyme replacement therapy","volume":"279","author":"Dhami","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb1575","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1021\/mp500241y","article-title":"Clathrin-mediated endocytosis is impaired in type A-B Niemann-pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement","volume":"11","author":"Rappaport","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.004_bb1580","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ana.20807","article-title":"Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease","volume":"59","author":"Fukuda","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.addr.2017.05.004_bb1585","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/14084","article-title":"Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases","volume":"1","author":"Puri","year":"1999","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb1590","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00018-015-2105-x","article-title":"Endocytic membrane trafficking and neurodegenerative disease","volume":"73","author":"Schreij","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb1595","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acs.molpharmaceut.5b00542","article-title":"A comparative study on the alterations of endocytic pathways in multiple lysosomal storage disorders","volume":"13","author":"Rappaport","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.004_bb1600","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","article-title":"Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction","volume":"111","author":"Ginns","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1605","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4161\/fly.26630","article-title":"Mutations in palmitoyl-protein thioesterase 1 alter exocytosis and endocytosis at synapses in drosophila larvae","volume":"7","author":"Aby","year":"2013","journal-title":"Fly"},{"key":"10.1016\/j.addr.2017.05.004_bb1610","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1038\/emboj.2010.237","article-title":"Lysosomal fusion and SNARE function are impaired by cholesterol accumulation in lysosomal storage disorders","volume":"29","author":"Fraldi","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.addr.2017.05.004_bb1615","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbamcr.2005.06.009","article-title":"Secrets of caveolae- and lipid raft-mediated endocytosis revealed by mammalian viruses","volume":"1746","author":"Pelkmans","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.004_bb1620","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1021\/mp5005959","article-title":"Altered clathrin-independent endocytosis in type a Niemann-pick disease cells and rescue by ICAM-1-targeted enzyme delivery","volume":"12","author":"Rappaport","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.addr.2017.05.004_bb1625","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1016\/S0021-9258(18)45483-X","article-title":"Low density lipoprotein (LDL)-mediated suppression of cholesterol synthesis and LDL uptake is defective in Niemann-pick type C fibroblasts","volume":"262","author":"Liscum","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb1630","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1091\/mbc.e09-01-0005","article-title":"Glycolipid trafficking in drosophila undergoes pathway switching in response to aberrant cholesterol levels","volume":"21","author":"Hortsch","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.addr.2017.05.004_bb1635","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4049\/jimmunol.168.1.298","article-title":"Ceramide-rich membrane rafts mediate CD40 clustering","volume":"168","author":"Grassme","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2017.05.004_bb1640","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S8756-3282(01)00679-2","article-title":"Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease","volume":"30","author":"Monroy","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.addr.2017.05.004_bb1645","doi-asserted-by":"crossref","first-page":"18065","DOI":"10.1523\/JNEUROSCI.0498-13.2013","article-title":"CLN3 loss disturbs membrane microdomain properties and protein transport in brain endothelial cells","volume":"33","author":"Tecedor","year":"2013","journal-title":"The Journal of neuroscience: the official journal of the Society for Neuroscience"},{"key":"10.1016\/j.addr.2017.05.004_bb1650","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0962-8924(02)02399-1","article-title":"Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease","volume":"12","author":"Marks","year":"2002","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb1655","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/BC.2009.009","article-title":"Mannose 6-phosphate receptor-dependent endocytosis of lysosomal enzymes is increased in sulfatide-storing kidney cells","volume":"390","author":"Klein","year":"2009","journal-title":"Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb1660","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/wnan.73","article-title":"New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders","volume":"2","author":"Muro","year":"2010","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.addr.2017.05.004_bb1665","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1517\/21678707.2013.780970","article-title":"Emerging therapies and therapeutic concepts for lysosomal storage diseases","volume":"1","author":"Kirkegaard","year":"2013","journal-title":"Expert Opinion on Orphan Drugs"},{"key":"10.1016\/j.addr.2017.05.004_bb1670","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.0308728100","article-title":"Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice","volume":"101","author":"LeBowitz","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1675","doi-asserted-by":"crossref","first-page":"35037","DOI":"10.1074\/jbc.M402630200","article-title":"Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase","volume":"279","author":"Prince","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb1680","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbrc.2005.05.207","article-title":"Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain","volume":"337","author":"Lee","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb1685","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ymthe.2005.02.031","article-title":"Defining the pathway for tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice","volume":"12","author":"Orii","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1690","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/90242","article-title":"The HIV tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors","volume":"19","author":"Xia","year":"2001","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb1695","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1471-4159.2007.05030.x","article-title":"Cellular uptake and lysosomal delivery of galactocerebrosidase tagged with the HIV tat protein transduction domain","volume":"104","author":"Zhang","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.addr.2017.05.004_bb1700","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2007.10.046","article-title":"Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides","volume":"354","author":"Jones","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2017.05.004_bb1705","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0014-4886(84)90192-4","article-title":"A study of intrathecal, cerebrospinal fluid-to-brain exchange","volume":"86","author":"Aird","year":"1984","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.addr.2017.05.004_bb1710","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS One"},{"issue":"Suppl. 1","key":"10.1016\/j.addr.2017.05.004_bb1715","first-page":"S124","article-title":"Novel treatments and future perspectives: outcomes of intrathecal drug delivery","volume":"47","author":"Dickson","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1720","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/0023210-200923010-00003","article-title":"Getting into the brain: approaches to enhance brain drug delivery","volume":"23","author":"Patel","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.addr.2017.05.004_bb1725","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/156652306776359522","article-title":"Cell and gene-based therapies for the lysosomal storage diseases","volume":"6","author":"Hodges","year":"2006","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1730","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1651-2227.2008.00660.x","article-title":"CNS-directed gene therapy for lysosomal storage diseases","volume":"97","author":"Sands","year":"2008","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.addr.2017.05.004_bb1735","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.gt.3302735","article-title":"Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice","volume":"13","author":"Watson","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1740","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/0271678X15614589","article-title":"Pharmacologic manipulation of lysosomal enzyme transport across the blood-brain barrier","volume":"36","author":"Urayama","year":"2016","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1745","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0169-409X(01)00141-7","article-title":"Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo","volume":"49","author":"Schnitzer","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.004_bb1750","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/bit.22135","article-title":"Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse","volume":"102","author":"Boado","year":"2009","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2017.05.004_bb1755","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/bit.21602","article-title":"Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier","volume":"99","author":"Boado","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2017.05.004_bb1760","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ymthe.2005.11.007","article-title":"AAV transcytosis through barrier epithelia and endothelium","volume":"13","author":"Di Pasquale","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1765","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1128\/JVI.74.23.11359-11366.2000","article-title":"Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium","volume":"74","author":"Xia","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2017.05.004_bb1770","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/bc900382q","article-title":"Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase","volume":"21","author":"Lu","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb1775","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/bit.24795","article-title":"Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor","volume":"110","author":"Boado","year":"2013","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2017.05.004_bb1780","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1046\/j.1471-4159.2002.01201.x","article-title":"High transcytosis of melanotransferrin (P97) across the blood-brain barrier","volume":"83","author":"Demeule","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.addr.2017.05.004_bb1785","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/jpet.107.131318","article-title":"Identification and design of peptides as a new drug delivery system for the brain","volume":"324","author":"Demeule","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1790","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.addr.2017.05.004_bb1795","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11095-004-1880-0","article-title":"Pharmacokinetic and tissue distribution mechanism of mouse recombinant heat shock protein 70 in mice","volume":"22","author":"Takemoto","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2017.05.004_bb1800","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1073\/pnas.0702170104","article-title":"Targeted delivery of proteins across the blood-brain barrier","volume":"104","author":"Spencer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1805","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1523\/JNEUROSCI.4785-13.2014","article-title":"Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase a","volume":"34","author":"Bockenhoff","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.addr.2017.05.004_bb1810","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.mehy.2014.01.029","article-title":"Lysosomal enzymes may cross the blood-brain-barrier by pinocytosis: implications for enzyme replacement therapy","volume":"82","author":"Baldo","year":"2014","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.addr.2017.05.004_bb1815","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1073\/pnas.0506892102","article-title":"Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII","volume":"102","author":"Vogler","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1820","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/bies.201100076","article-title":"Exosome nanotechnology: an emerging paradigm shift in drug delivery: exploitation of exosome nanovesicles for systemic in vivo delivery of RNAi heralds new horizons for drug delivery across biological barriers","volume":"33","author":"Lakhal","year":"2011","journal-title":"BioEssays"},{"key":"10.1016\/j.addr.2017.05.004_bb1825","series-title":"Exosomes Useful to Treat Lysosomal Storage Disease","author":"Tarnopolsky","year":"2016"},{"key":"10.1016\/j.addr.2017.05.004_bb1830","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","article-title":"Intranasal insulin improves memory in humans","volume":"29","author":"Benedict","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.addr.2017.05.004_bb1835","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb1840","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2012.02.006","article-title":"Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration","volume":"106","author":"Wolf","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1845","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.ymgme.2013.12.260","article-title":"Novel transporters for enzyme replacement therapy","volume":"111","author":"Tong","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2017.05.004_bb1850","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/wnan.1157","article-title":"Recent advances in stealth coating of nanoparticle drug delivery systems","volume":"4","author":"Amoozgar","year":"2012","journal-title":"Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology"},{"key":"10.1016\/j.addr.2017.05.004_bb1855","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1096\/fj.04-2747rev","article-title":"Nanomedicine: current status and future prospects","volume":"19","author":"Moghimi","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.addr.2017.05.004_bb1860","doi-asserted-by":"crossref","unstructured":"L.H. Tostanoski, Y-C. Chiu, J.M. Gammon, T. Simon, J.I. Andorko, J.S. Bromberg, C.M. Jewell, Reprogramming the local lymph node microenvironment promotes tolerance that is systemic and antigen specific, Cell Rep., 16 (2016) 2940\u20132952.","DOI":"10.1016\/j.celrep.2016.08.033"},{"key":"10.1016\/j.addr.2017.05.004_bb1865","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2010.10.025","article-title":"Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers","volume":"150","author":"Calderon","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.004_bb1870","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1124\/jpet.105.098970","article-title":"Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1","volume":"317","author":"Muro","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb1875","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.004_bb1880","first-page":"5","article-title":"Drug delivery and targeting","volume":"392","author":"Langer","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb1885","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","article-title":"Biodegradable nanoparticles for drug and gene delivery to cells and tissue","volume":"55","author":"Panyam","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.004_bb1890","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.addr.2008.04.001","article-title":"Materials for advanced drug delivery in the 21st century: a focus area for advanced drug delivery reviews","volume":"60","author":"Ghandehari","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.004_bb1895","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.1074972","article-title":"Polymer vesicles","volume":"297","author":"Discher","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.addr.2017.05.004_bb1900","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.addr.2009.08.001","article-title":"Polymer therapeutics: clinical applications and challenges for development","volume":"61","author":"Vicent","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.004_bb1905","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/10010065","article-title":"Polymeric particulates to improve oral bioavailability of peptide drugs","volume":"10","author":"Delie","year":"2005","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2017.05.004_bb1910","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0168-3659(01)00486-2","article-title":"Design of biodegradable particles for protein delivery","volume":"78","author":"Vila","year":"2002","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"key":"10.1016\/j.addr.2017.05.004_bb1915","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/187152006778699095","article-title":"New generation of liposomal drugs for cancer","volume":"6","author":"Minko","year":"2006","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb1920","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1359-0286(02)00117-1","article-title":"Biodegradable nanoparticles for drug delivery and targeting","volume":"6","author":"Hans","year":"2002","journal-title":"Curr. Opinion Solid State Mater. Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb1925","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0378-5173(03)00391-0","article-title":"Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers","volume":"265","author":"El-Sayed","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2017.05.004_bb1930","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1601-6343.2005.00336.x","article-title":"'Smart' delivery systems for biomolecular therapeutics","volume":"8","author":"Stayton","year":"2005","journal-title":"Orthod Craniofac Res"},{"key":"10.1016\/j.addr.2017.05.004_bb1935","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.addr.2006.09.009","article-title":"Multifunctional nanocarriers","volume":"58","author":"Torchilin","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2017.05.004_bb1940","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jconrel.2015.09.055","article-title":"Targeted endothelial nanomedicine for common acute pathological conditions","volume":"219","author":"Shuvaev","year":"2015","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"key":"10.1016\/j.addr.2017.05.004_bb1945","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrd3499","article-title":"Bio-inspired, bioengineered and biomimetic drug delivery carriers","volume":"10","author":"Yoo","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2017.05.004_bb1950","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/bj1640439","article-title":"Rapid partial purification of placental glucocerebroside beta-glucosidase and its entrapment in liposomes","volume":"164","author":"Braidman","year":"1977","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.addr.2017.05.004_bb1955","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1042\/bj1290123","article-title":"Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats","volume":"129","author":"Gregoriadis","year":"1972","journal-title":"Biochem. J."},{"key":"10.1016\/j.addr.2017.05.004_bb1960","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1042\/bst0021014","article-title":"Alpha-mannosidase in zinc-deficient rats. Possibility of liposomal therapy in mannosidosis","volume":"2","author":"Patel","year":"1974","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.addr.2017.05.004_bb1965","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1620\/tjem.136.219","article-title":"Delivery of fungal beta-galactosidase to rat brain by means of liposomes","volume":"136","author":"Takada","year":"1982","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb1970","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0006-291X(85)80212-6","article-title":"Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher)","volume":"127","author":"Umezawa","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.addr.2017.05.004_bb1975","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/0005-2736(77)90028-1","article-title":"Enzyme therapy. VI: comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes","volume":"464","author":"Steger","year":"1977","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.004_bb1980","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1073\/pnas.72.1.88","article-title":"A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells","volume":"72","author":"Weissmann","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb1985","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/(SICI)1097-4547(19970201)47:3<341::AID-JNR12>3.0.CO;2-4","article-title":"Delivery of liposome-sequestered hydrophobic proteins to lysosomes of normal and Batten disease cells","volume":"47","author":"Ansari","year":"1997","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.addr.2017.05.004_bb1990","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0304-4165(94)90113-9","article-title":"Enhanced intracellular stability and efficacy of PEG modified dextranase in the treatment of a model storage disorder","volume":"1199","author":"Mumtaz","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.addr.2017.05.004_bb1995","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/adhm.201500746","article-title":"Alpha-galactosidase-a loaded-nanoliposomes with enhanced enzymatic activity and intracellular penetration","volume":"5","author":"Cabrera","year":"2016","journal-title":"Advanced Healthcare Materials"},{"key":"10.1016\/j.addr.2017.05.004_bb2000","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/1061186X.2010.550921","article-title":"Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B","volume":"19","author":"Koshkaryev","year":"2011","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2017.05.004_bb2005","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1021\/bc200336j","article-title":"Screening and optimization of ligand conjugates for lysosomal targeting","volume":"22","author":"Meerovich","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb2010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2217\/nnm.12.138","article-title":"Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro","volume":"8","author":"Thekkedath","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2017.05.004_bb2015","doi-asserted-by":"crossref","unstructured":"Y. Li, Y. Pei, X. Zhang, Z. Gu, Z. Zhou, W. Yuan, J. Zhou, J. Zhu, X. Gao, PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats, J Control Release, 71 (201) 203\u2013211.","DOI":"10.1016\/S0168-3659(01)00218-8"},{"key":"10.1016\/j.addr.2017.05.004_bb2020","doi-asserted-by":"crossref","first-page":"16352","DOI":"10.1021\/ja306866w","article-title":"The effect of monomer order on the hydrolysis of biodegradable poly(lactic-co-glycolic acid) repeating sequence copolymers","volume":"134","author":"Li","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2017.05.004_bb2025","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/15548627.2015.1136769","article-title":"Nanoparticles restore lysosomal acidification defects: implications for Parkinson and other lysosomal-related diseases","volume":"12","author":"Bourdenx","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.addr.2017.05.004_bb2030","series-title":"ICAM-1-Targeted Nanocarriers Provide Efficient Targeting, Transport across the BBB, and Uniform Distribution and Effects of Therapeutic Enzymes in the Brain","first-page":"34","author":"Bhowmick","year":"2011"},{"key":"10.1016\/j.addr.2017.05.004_bb2035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156452","article-title":"Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders","volume":"11","author":"Salvalaio","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2017.05.004_bb2040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jbm.a.30348","article-title":"Biological evaluation of calcium alginate microspheres as a vehicle for the localized delivery of a therapeutic enzyme","volume":"74","author":"Barrias","year":"2005","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2017.05.004_bb2045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/psc.2430","article-title":"Peptide-mediated cell penetration and targeted delivery of gold nanoparticles into lysosomes","volume":"18","author":"Dekiwadia","year":"2012","journal-title":"Journal of Peptide Science: An Official Publication of the European Peptide Society"},{"key":"10.1016\/j.addr.2017.05.004_bb2050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/mt.2010.78","article-title":"Guanidinylated neomycin mediates heparan sulfate-dependent transport of active enzymes to lysosomes","volume":"18","author":"Sarrazin","year":"2010","journal-title":"Molecular Therapy: the Journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.addr.2017.05.004_bb2055","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/bm2003384","article-title":"pH-responsive polysaccharide-based polyelectrolyte complexes as nanocarriers for lysosomal delivery of therapeutic proteins","volume":"12","author":"Giannotti","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.addr.2017.05.004_bb2060","doi-asserted-by":"crossref","first-page":"10395","DOI":"10.1007\/s00253-016-7689-z","article-title":"Alpha-galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease","volume":"100","author":"Lee","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb2065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymthe.2005.07.687","article-title":"Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis","volume":"13","author":"Muro","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb2070","series-title":"Endothelial Biomedicine","first-page":"1058","article-title":"Intercellular Adhesion Molecule 1 and Vascular Cell Adhesion Molecule 1","author":"Muro","year":"2007"},{"key":"10.1016\/j.addr.2017.05.004_bb2075","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4049\/jimmunol.137.4.1270","article-title":"A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1","volume":"137","author":"Rothlein","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.addr.2017.05.004_bb2080","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/346425a0","article-title":"Adhesion receptors of the immune system","volume":"346","author":"Springer","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.addr.2017.05.004_bb2085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1734-1140(09)70004-0","article-title":"ICAM-1 signaling in endothelial cells","volume":"61","author":"Lawson","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.addr.2017.05.004_bb2090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2015.07.043","article-title":"Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: synergy between physical, chemical and biological approaches","volume":"68","author":"Anselmo","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.004_bb2095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2310\/7290.2007.00005","article-title":"Inflammation-specific T1 imaging using anti-intercellular adhesion molecule 1 antibody-conjugated gadolinium diethylenetriaminepentaacetic acid","volume":"6","author":"Choi","year":"2007","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.addr.2017.05.004_bb2100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jacc.2003.07.048","article-title":"Intravascular ultrasound molecular imaging of atheroma components in vivo","volume":"43","author":"Hamilton","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2017.05.004_bb2105","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1016\/j.biomaterials.2010.06.038","article-title":"Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions","volume":"31","author":"Park","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2017.05.004_bb2110","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/bit.20625","article-title":"Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx","volume":"92","author":"Weller","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2017.05.004_bb2115","doi-asserted-by":"crossref","first-page":"14710","DOI":"10.1073\/pnas.1408556111","article-title":"ICAM-1 as a molecular target for triple negative breast cancer","volume":"111","author":"Guo","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb2120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2010.10.031","article-title":"Enhanced endothelial delivery and biochemical effects of alpha-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease","volume":"149","author":"Hsu","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.004_bb2125","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1002\/adfm.201600084","article-title":"Chitosan-alginate microcapsules provide gastric protection and intestinal release of ICAM-1-targeting nanocarriers, enabling GI targeting in vivo","volume":"26","author":"Ghaffarian","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2017.05.004_bb2130","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/jpet.107.133298","article-title":"Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers","volume":"325","author":"Garnacho","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb2135","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0014-5793(94)01350-A","article-title":"Adhesion molecules: a new target for immunoliposome-mediated drug delivery","volume":"357","author":"Bloemen","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.addr.2017.05.004_bb2140","doi-asserted-by":"crossref","first-page":"15895","DOI":"10.1073\/pnas.2631433100","article-title":"Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo","volume":"100","author":"Sakhalkar","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2017.05.004_bb2145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.CIR.98.1.1","article-title":"Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells","volume":"98","author":"Villanueva","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2017.05.004_bb2150","first-page":"1109","article-title":"Early detection of oleic acid-induced lung injury in rats using (111)in-labeled anti-rat intercellular adhesion molecule-1","volume":"42","author":"Weiner","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb2155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejps.2009.02.008","article-title":"ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells","volume":"37","author":"Chittasupho","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb2160","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cphc.200800296","article-title":"Oxygen microscopy by two-photon-excited phosphorescence","volume":"9","author":"Finikova","year":"2008","journal-title":"ChemPhysChem"},{"key":"10.1016\/j.addr.2017.05.004_bb2165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2967\/jnumed.107.045302","article-title":"In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium","volume":"49","author":"Rossin","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.addr.2017.05.004_bb2170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/acs.bioconjchem.5b00641","article-title":"Vascular accessibility of endothelial targeted ferritin nanoparticles","volume":"27","author":"Khoshnejad","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb2175","doi-asserted-by":"crossref","first-page":"26256","DOI":"10.1074\/jbc.M500835200","article-title":"Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms","volume":"280","author":"Grassme","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.addr.2017.05.004_bb2180","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1242\/jcs.00367","article-title":"A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1","volume":"116","author":"Muro","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.addr.2017.05.004_bb2185","doi-asserted-by":"crossref","first-page":"L809","DOI":"10.1152\/ajplung.00311.2005","article-title":"Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+\/H+ exchanger proteins","volume":"290","author":"Muro","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.addr.2017.05.004_bb2190","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/jcb.22798","article-title":"Recycling and LFA-1-dependent trafficking of ICAM-1 to the immunological synapse","volume":"111","author":"Jo","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.addr.2017.05.004_bb2195","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.111.244186","article-title":"Intercellular adhesion molecule 1 engagement modulates sphingomyelinase and ceramide, supporting uptake of drug carriers by the vascular endothelium","volume":"32","author":"Serrano","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.addr.2017.05.004_bb2200","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2007-06-098657","article-title":"RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1","volume":"111","author":"Garnacho","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb2205","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2008.127","article-title":"Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers","volume":"16","author":"Muro","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2017.05.004_bb2210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2016.07.042","article-title":"Intra- and trans-cellular delivery of enzymes by direct conjugation with non-multivalent anti-ICAM molecules","volume":"238","author":"Ghaffarian","year":"2016","journal-title":"Journal of Controlled Release: Official Journal of the Controlled Release Society"},{"key":"10.1016\/j.addr.2017.05.004_bb2215","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1182\/blood-2004-12-4942","article-title":"ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow","volume":"106","author":"Yang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.addr.2017.05.004_bb2220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2012.06.007","article-title":"Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1","volume":"163","author":"Ghaffarian","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2017.05.004_bb2225","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1166\/jbn.2014.1718","article-title":"Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers","volume":"10","author":"Hsu","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2017.05.004_bb2230","unstructured":"C. Garnacho, R. Dhami, M. Solomon, E.H. Schuchman, S. Muro, Enhanced delivery and effects of acid sphingomyelinase by ICAM-1-targeted Nanocarriers in type B Niemann-pick disease mice, Mol Ther (minor revisions)."},{"key":"10.1016\/j.addr.2017.05.004_bb2235","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.nano.2011.08.014","article-title":"Enhanced delivery of alpha-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders","volume":"8","author":"Hsu","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2017.05.004_bb2240","series-title":"ICAM-1-Targeted Nanocarriers Attenuate Endothelial Release of Soluble ICAM-1, an Inflammatory Regulator","author":"Manthe","year":"2017"},{"key":"10.1016\/j.addr.2017.05.004_bb2245","doi-asserted-by":"crossref","first-page":"C1339","DOI":"10.1152\/ajpcell.00099.2003","article-title":"Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress","volume":"285","author":"Muro","year":"2003","journal-title":"Am J Physiol Cell Physiol"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X17300601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X17300601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:37:34Z","timestamp":1759207054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X17300601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":449,"alternative-id":["S0169409X17300601"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2017.05.004","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2017.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}